Clinical Trials Logo

Clinical Trial Summary

The project examines the hypothesis that monoclonal allergen-neutralizing antibodies can be recombinantly produced from B lymphocytes isolated from pollen allergic patients. Patient samples suitable for antibody cloning are selected based on seroprofiling for the respective allergens. The study aims at isolating lymphocytes from patients with potential allergen-neutralizing IgG in serum and to clone antibodies from antibody gene sequences obtained from B cells of those patients.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03727399
Study type Observational
Source Mabylon AG
Contact
Status Enrolling by invitation
Phase
Start date October 1, 2018
Completion date December 31, 2025

See also
  Status Clinical Trial Phase
Completed NCT01500642 - Comparison of the Efficacy and the Safety of Different Schedules of Administration of Sub-lingual Immunotherapy Phase 3
Completed NCT00263627 - Safety and Efficacy of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Allergoid Preparation of Birch Pollen Allergens Phase 3
Terminated NCT04874714 - Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis Phase 3
Completed NCT04622917 - Methylprednisolone Injections Treating Birch Pollen Induced Allergic Rhinitis. Phase 4